Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength and potential resilience amidst current market conditions.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.78651	$5.71M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.20	$547.49M	★★★★★★
RLX Technology (NYSE:RLX)	$1.60	$2.07B	★★★★★★
ARC Document Solutions (NYSE:ARC)	$3.42	$147.91M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.61	$51.81M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.70	$113.74M	★★★★★★
Better Choice (NYSEAM:BTTR)	$1.7889	$3.24M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$1.07	$96.23M	★★★★★☆

Click here to see the full list of 760 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

CytoMed Therapeutics (NasdaqCM:GDTC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company specializing in the development of novel cell-based immunotherapies for treating human cancers and degenerative diseases in Malaysia and Singapore, with a market cap of $29.31 million.

Operations: The company generates revenue of SGD 0.45 million from its biotechnology startup segment.

Market Cap: $29.31M

CytoMed Therapeutics, a pre-revenue biopharmaceutical company with a market cap of US$29.31 million, is advancing its novel CAR-T cell therapy through the ANGELICA Trial in collaboration with Singapore's National University Hospital. This trial marks a significant step as it employs gamma delta T cells from healthy donors, potentially reducing costs and improving accessibility compared to traditional therapies. Despite reporting a reduced net loss of SGD 1.09 million for H1 2024, CytoMed remains unprofitable but benefits from having more cash than debt and sufficient short-term assets to cover liabilities, supporting its ongoing research endeavors.

• Unlock comprehensive insights into our analysis of CytoMed Therapeutics stock in this financial health report.
• Explore CytoMed Therapeutics' analyst forecasts in our growth report.

Aclaris Therapeutics (NasdaqGS:ACRS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases in the United States, with a market cap of $90.61 million.

Operations: The company generates revenue through its Therapeutics segment, which accounts for $29.46 million, and its Contract Research segment, contributing $19.09 million.

Market Cap: $90.61M

Aclaris Therapeutics, with a market cap of US$90.61 million, is actively progressing its clinical pipeline for immune-inflammatory diseases, recently dosing the first patient in a Phase 2a trial for ATI-2138 targeting atopic dermatitis. Despite being unprofitable and not expected to achieve profitability in the next three years, Aclaris has reduced its losses over five years and maintains sufficient cash reserves to cover liabilities and sustain operations for over two years without debt concerns. Recent earnings show improved revenue of US$2.77 million for Q2 2024, reflecting ongoing efforts to stabilize financial performance amidst volatility reduction.

• Jump into the full analysis health report here for a deeper understanding of Aclaris Therapeutics.
• Evaluate Aclaris Therapeutics' prospects by accessing our earnings growth report.

LFTD Partners (OTCPK:LIFD)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: LFTD Partners Inc., through its subsidiary Lifted Made, engages in the development, manufacturing, and sale of hemp-derived cannabinoid products as well as psychoactive and alternative lifestyle products related to nicotine, tobacco, and marijuana both in the United States and internationally, with a market cap of $10.38 million.

Operations: The company generates revenue from its Tobacco Products segment, which amounts to $46.78 million.

Market Cap: $10.38M

LFTD Partners, with a market cap of US$10.38 million, is navigating challenges in the hemp-derived cannabinoid and alternative lifestyle product markets. Recent earnings for Q2 2024 revealed sales of US$9.49 million, down from US$12.52 million the previous year, resulting in a net loss of US$0.52 million compared to a prior net income of US$1.66 million. Despite increased debt levels over five years, the company maintains more cash than its total debt and has short-term assets exceeding liabilities by a comfortable margin. The board and management are experienced but face heightened share price volatility recently.

• Click here to discover the nuances of LFTD Partners with our detailed analytical financial health report.
• Learn about LFTD Partners' historical performance here.

Where To Now?

• Click here to access our complete index of 760 US Penny Stocks.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com